FierceBiotech Apr 9, 2026 Judge rules that HHS must face states' lawsuit over RFK Jr.'s agency overhaul, massive layoffs
FierceBiotech Apr 9, 2026 'It’s going to be huge': The 'diabolical' molecule poised to become biotech's next gold rush
FierceBiotech Apr 9, 2026 Gilead pays Kymera $45M to glue preclinical protein degrader onto burgeoning oncology pipeline
FierceBiotech Apr 9, 2026 Boehringer hands over funding, marketing rights for Click’s digital therapeutic
FierceBiotech Apr 9, 2026 In a first, a CAR-T cell therapy drives 3 autoimmune diseases into remission in a single patient
FierceBiotech Apr 9, 2026 Avalyn plans IPO to fund phase 3 trials of inhaled versions of approved respiratory drugs
FierceBiotech Apr 9, 2026 Roche takes 'leap of faith' with $20M bet on C4T’s antibody-targeted protein degraders
FierceBiotech Apr 8, 2026 Medline hit with FDA warning letter over defective heart syringes, safety hazards
FierceBiotech Apr 8, 2026 Artivion nabs PMA clearance for aortic stent graft system, triggers Endospan buyout option
FierceBiotech Apr 8, 2026 With $2B Novo deal in the books, Vivtex isn't 'limited to being just a drug delivery company': CEO
FierceBiotech Apr 8, 2026 Astellas unearths Dyno muscle disorder AAV capsid with $15M option agreement
FierceBiotech Apr 8, 2026 Akari locks arms with WuXi XDC to develop and manufacture novel ADC treatment
FierceBiotech Apr 8, 2026 Jeito hails $1.2B as 'largest raise ever' for independent biopharma-focused European fund
FierceBiotech Apr 8, 2026 OrbiMed’s Sidewinder slides toward clinic with $137M series B for antibody-drug conjugates
FierceBiotech Apr 8, 2026 With 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger'
FierceBiotech Apr 7, 2026 Lilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinic